ClinicalTrials.gg
Enrolling by invitationNCT07425106Updated Feb 25, 2026

Comparative Study of High Performance Low-Cost Optical Coherence Tomography (Stage 1B, 2 and 3)

An interventional study of retinal imaging with low-cost OCT-a/LCI device in Optical Coherence Tomography of Retina and Alzheimer Disease, sponsored by Duke University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Duke University · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Alzheimer Disease by Duke University — 4 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · Duke University.

Planned enrollment
5th of 10
82 · median 56
Started
2026
the only one that year
No phase
6 of 15
2 open now
Registered
15th of 15
by date

Among the 15 studies in Alzheimer Disease by Duke University, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 15th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 15 studies in Alzheimer Disease by Duke University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Alzheimer Disease by Duke University, or all of them as a file.
02

Study summary

The purpose of this study is to complete performance testing of our custom optical coherence tomography (OCT) device to verify it can deliver retinal images of similar quality to a commercial OCT device. We will then add an angle-resolved low coherence interferometry (a/LCI module) to the device to make measurements of retinal tissue structure.

Read the detailed description

There is some evidence that certain changes in retinal structures could be an indicator of Alzheimer's disease (AD). We are developing a new technology that combines optical coherence tomography (OCT) and angle-resolved low coherence interferometry (a/LCI) to make light scattering measurements of retinal tissue structure. The first objective of this study is to compare performance characteristics of our custom OCT instrument to a commercial OCT instrument. Once we have optimized our device, the second objective will be to use the custom OCT-a/LCI device to identify retinal structure changes that could be possible AD biomarkers.

For this study, the team will recruit volunteers to attend one study visit that is about 30 minutes long. For arm 1A (registered under NCT05530460), this visit will include examination with our custom OCT instrument, followed by examination with a commercial OCT system. For arms 1B and 2/3, the visit will include examination with the custom OCT-a/LCI instrument.

This study will recruit participants with Alzheimer's disease and healthy controls.

03

Conditions studied

  • Optical Coherence Tomography of Retina
  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

All Participants:

Inclusion Criteria:

  • able to provide

Exclusion Criteria:

  • potentially confounding ocular conditions, such as: glaucoma, current corneal injury, retinal damage, diabetes, corrected distance visual acuity worse than 20/40
  • eyes that have had intraocular surgery or retinal surgery, other than cataract surgery

Participants with Alzheimer's Disease:

Inclusion:

- mild cognitive impairment (MCI) or dementia due to Alzheimer's disease, confirmed by A/T/N classification

Healthy Controls:

Exclusion:

- has a memory or other neurodegenerative diagnosis (including mild cognitive impairment, Parkinson's disease, Alzheimer's disease, traumatic brain injury, post-traumatic stress disorder)

If two eyes satisfy the inclusion / exclusion criteria, both eyes will be included in the study. If only one eye satisfies the criteria, only the qualifying eye will be included in the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Performance Testing of OCT-a/LCI (1B)

    Performance testing of custom OCT-a/LCI device.

    Device: retinal imaging with low-cost OCT-a/LCI device

  • Experimental
    Retinal Morphology (2/3)

    examination with OCT-a/LCI device to examine retinal morphology characteristics of participants with Alzheimer's disease and healthy controls

    Device: retinal imaging with low-cost OCT-a/LCI device

Interventions

  • Deviceretinal imaging with low-cost OCT-a/LCI device

    retinal imaging with low-cost OCT-a/LCI device

06

What researchers measure

Primary outcomes

  1. Number of Participants with Acceptable OCT Image Quality as Measured by Low-Cost OCT Device

    measured by: ability to see clearly defined and recognizable structures of the retina with the low-cost OCT device.

    Time frame: during study procedures (30 minutes)

  2. RNFL Thickness

    Thickness of retinal nerve fiber layer, measured in microns

    Time frame: during study procedures (30 minutes)

  3. GCL Thickness

    Thickness of ganglion cell layer, measured in microns.

    Time frame: during study procedures (30 minutes)

Secondary outcomes

  1. Contrast-to-Noise Ratio (CNR)

    Measure of OCT image quality comparing level of image contrast to level of background noise. CNR = (mean of signal of region of interest \[i.e., retina\] - mean of background noise) divided by square root of (the square of the standard deviation of the region of interest + the square of the standard deviation of the background noise). Therefore, CNR is unitless.

    Time frame: during study procedures (30 minutes)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 12 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 20, 2026
StartActual
Feb 13, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07425106
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Feb 13, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 25, 2026

Study contacts

Adam Wax, Ph.D.
principal investigator · Duke University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion